Product
Parsaclisib + Ibrutinib
1 clinical trial
1 indication
Indication
B-Cell MalignanciesClinical trial
A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)Status: Recruiting, Estimated PCD: 2024-09-30